JP6741773B2 - 炎症状態の急性増悪の治療のための投与レジメン - Google Patents

炎症状態の急性増悪の治療のための投与レジメン Download PDF

Info

Publication number
JP6741773B2
JP6741773B2 JP2018547430A JP2018547430A JP6741773B2 JP 6741773 B2 JP6741773 B2 JP 6741773B2 JP 2018547430 A JP2018547430 A JP 2018547430A JP 2018547430 A JP2018547430 A JP 2018547430A JP 6741773 B2 JP6741773 B2 JP 6741773B2
Authority
JP
Japan
Prior art keywords
days
dose
cyanobenzoyl
pyrazol
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018547430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507785A (ja
JP2019507785A5 (enExample
Inventor
オーフォード，コリン
クラーク，シリル
ファレル，コルム
パーキン，ジャクリーン
バック，ステファン デ
バック，ステファン デ
Original Assignee
メレオ バイオファーマ １ リミテッド
メレオ バイオファーマ １ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メレオ バイオファーマ １ リミテッド, メレオ バイオファーマ １ リミテッド filed Critical メレオ バイオファーマ １ リミテッド
Publication of JP2019507785A publication Critical patent/JP2019507785A/ja
Publication of JP2019507785A5 publication Critical patent/JP2019507785A5/ja
Application granted granted Critical
Publication of JP6741773B2 publication Critical patent/JP6741773B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018547430A 2016-03-08 2016-03-08 炎症状態の急性増悪の治療のための投与レジメン Active JP6741773B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2016/050635 WO2017153701A1 (en) 2016-03-08 2016-03-08 Dosage regimen for the treatment of acute exacerbations of inflammatory conditions

Publications (3)

Publication Number Publication Date
JP2019507785A JP2019507785A (ja) 2019-03-22
JP2019507785A5 JP2019507785A5 (enExample) 2019-05-09
JP6741773B2 true JP6741773B2 (ja) 2020-08-19

Family

ID=55646778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018547430A Active JP6741773B2 (ja) 2016-03-08 2016-03-08 炎症状態の急性増悪の治療のための投与レジメン

Country Status (9)

Country Link
US (1) US10617674B2 (enExample)
JP (1) JP6741773B2 (enExample)
KR (1) KR20180119597A (enExample)
AU (1) AU2016397046B2 (enExample)
BR (1) BR112018067784A2 (enExample)
CA (1) CA3016368A1 (enExample)
MX (1) MX389563B (enExample)
RU (1) RU2709509C1 (enExample)
WO (1) WO2017153701A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385717B (es) * 2016-03-08 2025-03-18 Mereo Biopharma 1 Ltd Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica.
GB201612240D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
GB201612238D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
JP7280627B2 (ja) * 2017-12-11 2023-05-24 メレオ バイオファーマ １ リミテッド 慢性閉塞性肺疾患の急性増悪の処置における３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6598603B1 (en) 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
RU2381219C2 (ru) * 2003-06-26 2010-02-10 Новартис Аг ПРОИЗВОДНЫЕ 5-ЧЛЕННЫХ ГЕТЕРОЦИКЛОВ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ p38
CN1832928B (zh) * 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
TWI439284B (zh) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
US20050277602A1 (en) * 2004-05-21 2005-12-15 Grunstein Michael M Methods employing agonists of P38 map kinase for the treatment of asthma
US20090270350A1 (en) * 2006-02-10 2009-10-29 Pfizer Inc. Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
LT2827860T (lt) * 2012-03-20 2016-12-12 Mereo Biopharma 1 Limited Pirazolo darinio panaudojimas stiprių lėtinės obstrukcinės plaučių ligos paūmėjimų gydymui

Also Published As

Publication number Publication date
JP2019507785A (ja) 2019-03-22
MX2018010781A (es) 2018-11-09
RU2709509C1 (ru) 2019-12-18
US10617674B2 (en) 2020-04-14
WO2017153701A1 (en) 2017-09-14
MX389563B (es) 2025-03-20
AU2016397046A1 (en) 2018-09-06
AU2016397046B2 (en) 2022-05-12
US20190091203A1 (en) 2019-03-28
CA3016368A1 (en) 2017-09-14
BR112018067784A2 (pt) 2019-01-15
KR20180119597A (ko) 2018-11-02

Similar Documents

Publication Publication Date Title
US11129810B2 (en) Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
JP6741773B2 (ja) 炎症状態の急性増悪の治療のための投与レジメン
AU2018381874B2 (en) Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease
EP3585382B1 (en) Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
KR102899004B1 (ko) 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도
HK40020426B (en) Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
HK40020427B (en) Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention of acute exacerbations of chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190305

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200721

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200727

R150 Certificate of patent or registration of utility model

Ref document number: 6741773

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250